Paloma Partners Management Co reduced its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 15.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 13,804 shares of the company’s stock after selling 2,493 shares during the period. Paloma Partners Management Co’s holdings in IDEXX Laboratories were worth $2,159,000 as of its most recent SEC filing.
Other institutional investors also recently made changes to their positions in the company. Zions Bancorporation purchased a new position in IDEXX Laboratories in the third quarter valued at approximately $162,000. Benjamin F. Edwards & Company Inc. grew its position in shares of IDEXX Laboratories by 1,000.0% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 1,100 shares of the company’s stock worth $172,000 after acquiring an additional 1,000 shares during the last quarter. SignalPoint Asset Management LLC purchased a new position in shares of IDEXX Laboratories during the fourth quarter worth approximately $200,000. Ledyard National Bank grew its position in shares of IDEXX Laboratories by 58.9% during the fourth quarter. Ledyard National Bank now owns 1,295 shares of the company’s stock worth $203,000 after acquiring an additional 480 shares during the last quarter. Finally, Unio Capital LLC purchased a new position in shares of IDEXX Laboratories during the fourth quarter worth approximately $203,000. Institutional investors own 87.09% of the company’s stock.
In related news, VP Brian P. Mckeon sold 6,602 shares of IDEXX Laboratories stock in a transaction on Monday, February 5th. The shares were sold at an average price of $181.36, for a total value of $1,197,338.72. Following the transaction, the vice president now directly owns 47,040 shares in the company, valued at approximately $8,531,174.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bruce L. Claflin acquired 1,000 shares of the stock in a transaction that occurred on Wednesday, February 7th. The stock was purchased at an average price of $179.58 per share, for a total transaction of $179,580.00. Following the completion of the transaction, the director now owns 1,000 shares in the company, valued at $179,580. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 91,736 shares of company stock worth $16,193,502. 2.77% of the stock is currently owned by insiders.
IDEXX Laboratories, Inc. (NASDAQ IDXX) opened at $204.53 on Wednesday. IDEXX Laboratories, Inc. has a 1 year low of $146.09 and a 1 year high of $206.49. The company has a debt-to-equity ratio of -11.26, a current ratio of 0.97 and a quick ratio of 0.80. The firm has a market cap of $17,803.54, a price-to-earnings ratio of 64.67, a P/E/G ratio of 2.51 and a beta of 0.58.
IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Thursday, February 1st. The company reported $0.77 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.04. IDEXX Laboratories had a net margin of 13.36% and a negative return on equity of 432.19%. The firm had revenue of $506.00 million for the quarter, compared to analyst estimates of $490.51 million. During the same period last year, the firm posted $0.58 EPS. IDEXX Laboratories’s quarterly revenue was up 14.2% on a year-over-year basis. equities analysts anticipate that IDEXX Laboratories, Inc. will post 4.09 earnings per share for the current year.
A number of equities analysts have recently issued reports on IDXX shares. Zacks Investment Research upgraded shares of IDEXX Laboratories from a “hold” rating to a “strong-buy” rating and set a $214.00 target price on the stock in a research report on Monday, February 5th. BidaskClub lowered shares of IDEXX Laboratories from a “hold” rating to a “sell” rating in a research report on Saturday, December 16th. Bank of America raised their target price on shares of IDEXX Laboratories from $200.00 to $220.00 and gave the stock a “buy” rating in a research report on Friday, February 2nd. Piper Jaffray Companies raised their target price on shares of IDEXX Laboratories to $211.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Finally, Canaccord Genuity restated a “buy” rating and set a $210.00 target price on shares of IDEXX Laboratories in a research report on Monday, January 29th. One analyst has rated the stock with a sell rating, five have given a buy rating and two have assigned a strong buy rating to the company’s stock. IDEXX Laboratories presently has an average rating of “Buy” and a consensus price target of $194.00.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.